BIA reactions to Queen's Speech 2019

14 October 2019

“It’s great to hear the government recognizes the enormous contribution of the UK life sciences sector to the wider UK economy, which was highlighted at numerous points in today’s Queen’s speech,” Steve Bates, chief executive of the UK’s BioIndustry Association (BIA) in response to the opening of Parliament speech by the Monarch on behalf of the Prime Minister Boris Johnson’s government yesterday.

On clinical trials

“The UK has a long history of taking a leading role in regulatory science and novel trial design. It’s welcome news that the government wants the UK to continue to be at the frontier of the next generation of clinical development of breakthrough products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK